benzyl (S)-2-methyl-4-oxabutanoate | 152441-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl (S)-2-methyl-4-oxabutanoate
• 英文别名: benzyl (S)-2-methyl-4-oxobutanoate；benzyl (2S)-2-methyl-4-oxobutanoate
• CAS: 152441-67-3
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: GCWZBKJCMKNDOF-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl (S)-2-methyl-4-oxabutanoate 在 4-二甲氨基吡啶 、 palladium 10% on activated carbon 、 四丁基氟化铵 、 氢气 、 双(2-氧代-3-恶唑烷基)次磷酰氯 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 、 lithium bromide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 23.0h， 生成
  参考文献：
  名称：

  A Peptide-Embedded Trifluoromethyl Ketone Catalyst for Enantioselective Epoxidation

  摘要：

  The development of peptide-based oxidation catalysts that use a transiently generated dioxirane as the chemically active species is reported. The active catalyst is a chiral trifluoromethyl ketone (Tfk) with a pendant carboxylic acid that can be readily incorporated into a peptide. These peptides were capable of epoxidizing alkenes in high yield (up to 89%) and enantiomeric ratios (er) ranging from 69.0:31.0 to 91.0:9.0, depending on the alkene substitution pattern.

  DOI：

  10.1021/ol3000712
• 作为产物：
  描述：

  (R)-4-isopropyl-3-((S)-2-methylpent-4-enoyl)-5,5-diphenyloxazolidin-2-one 在 正丁基锂 、 臭氧 作用下， 以 四氢呋喃 、 hexanes 、 二氯甲烷 为溶剂， 反应 1.42h， 生成 benzyl (S)-2-methyl-4-oxabutanoate
  参考文献：
  名称：

  A Peptide-Embedded Trifluoromethyl Ketone Catalyst for Enantioselective Epoxidation

  摘要：

  The development of peptide-based oxidation catalysts that use a transiently generated dioxirane as the chemically active species is reported. The active catalyst is a chiral trifluoromethyl ketone (Tfk) with a pendant carboxylic acid that can be readily incorporated into a peptide. These peptides were capable of epoxidizing alkenes in high yield (up to 89%) and enantiomeric ratios (er) ranging from 69.0:31.0 to 91.0:9.0, depending on the alkene substitution pattern.

  DOI：

  10.1021/ol3000712

文献信息

• [EN] MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS<br/>[FR] COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU PROTÉASOME
  申请人：UNIV CORNELL

  公开号：WO2019075259A1

  公开（公告）日：2019-04-18

  The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R', R", X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

  本发明的化合物由具有以下式I和式(I')的化合物表示，其中取代基R1、R2、R2'、R3、R4、R5、R'、R"、X、Y和Z如本文所定义，取代基R1、R2、R3、R4、R5、R'、R"、X、Y和Z如本文所定义。这些化合物用于治疗细菌感染、寄生虫感染、真菌感染、癌症、免疫紊乱、自身免疫性疾病、神经退行性疾病和紊乱、炎症性疾病，或肌肉萎缩症，或用于为移植的器官或组织提供免疫抑制。
• The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives
  作者：Eugene J. Trybulski、Jing Zhang、Richard H. Kramss、Richard M. Mangano

  DOI：10.1021/jm00075a007

  日期：1993.11

  Previous pharmacological studies of methylated oxotremorine derivatives bearing substituents at the 3-, 4-, and 5-positions of the pyrrolidinone ring have been conducted using racemic mixtures, and not with optically active compounds. The synthesis and radioligand binding data of optically active, methylated oxotremorine derivatives at the 3- and 4-positions are described. There are significant pharmacological

  以前使用外消旋混合物而不是旋光性化合物进行了在吡咯烷酮环的3-，4-和5-位带有取代基的甲基化氧代苯丁胺衍生物的药理研究。描述了在3位和4位的旋光甲基化氧代苯丙氨酸衍生物的合成和放射性配体结合数据。3位和4位衍生物之间存在明显的药理差异。4位对映异构体具有弱的，近似相等的亲和力和类似拮抗剂的特征，而3位对映异构体具有显着不同的亲和力和部分激动剂类似的特征。
• Influence of the ester group during the enantioselective methylation of α-aldehyde esters via their chiral oxazolidine derivatives
  作者：Claude Agami、Franç¸ois Couty

  DOI：10.1016/s0040-4039(00)96806-0

  日期：1987.1

  Depending on the nature of the ester group, fair asymmetric induction (ee's up to 82%) can be attained in the title reaction.

  根据酯基的性质，可以在标题反应中获得公平的不对称诱导（ee高达82％）。
• MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
  申请人：Desai Manoj C.

  公开号：US20120237478A1

  公开（公告）日：2012-09-20

  The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
• US8486942B2
  申请人：——

  公开号：US8486942B2

  公开（公告）日：2013-07-16